array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(25) "Gsk Consumer Health, Inc."
["slug"]=>
string(32) "4abba-us-gsk-consumer-health-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/8434ac9a-9bf2-4877-a3a0-a4039c237204"
["description"]=>
string(518) "GSK Consumer Healthcare is a global business that discovers, develops, and manufactures innovative consumer healthcare products. It is an associate of GlaxoSmithKline plc, one of the world's largest healthcare companies. GSK Consumer Healthcare aims to become one of the world's most innovative, best performing, and trusted healthcare companies. Their goal is to improve lives through scientific innovation, build category-defining brands, and become Pakistan's first and best Fast Moving Consumer Healthcare Company."
["address_street"]=>
string(28) "184 Liberty Corner Rd Ste 78"
["address_place"]=>
string(6) "Warren"
["address_region"]=>
string(10) "New Jersey"
["founding_date"]=>
string(10) "1994-02-28"
["website_domain"]=>
string(7) "gsk.com"
["website_url"]=>
string(19) "https://www.gsk.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(300)
["article_count"]=>
int(458)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(60) "Market Round-Up: Best quarter in a year for European markets"
["snippet_en"]=>
string(212) "Global stock markets remained on an upbeat trajectory in March, with the European stock markets particularly robust in the first quarter. Banking and Energy stocks shone, outpacing the technology sector in March."
["url"]=>
string(104) "https://www.euronews.com/business/2024/03/29/market-round-up-best-quarter-in-a-year-for-european-markets"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/262bcf44-84c0-4cdf-9255-e0211fe95c1c"
["source"]=>
string(12) "euronews.com"
["publication_date"]=>
string(10) "2024-03-29"
["categories"]=>
array(3) {
[0]=>
string(15) "Market Movement"
[1]=>
string(24) "Quarterly/Annual Figures"
[2]=>
string(12) "Stock Market"
}
}
[1]=>
array(7) {
["title_en"]=>
string(72) "GSK earns 5,767 million euros in 2023, 67.1% less than the previous year"
["snippet_en"]=>
string(139) "The British pharmaceutical company's profits in the fourth quarter were 409.6 million euros, 76.6% less than in the same period of 2023...."
["url"]=>
string(109) "https://www.plantadoce.com/empresa/gsk-gana-5767-millones-de-euros-en-2023-un-671-menos-que-el-ano-precedente"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/4f0474f8-b14c-4fa4-bfed-d79cc713875f"
["source"]=>
string(14) "plantadoce.com"
["publication_date"]=>
string(10) "2024-01-31"
["categories"]=>
array(3) {
[0]=>
string(24) "Quarterly/Annual Figures"
[1]=>
string(31) "Financial Update/Profit Warning"
[2]=>
string(18) "Financial Distress"
}
}
[2]=>
array(7) {
["title_en"]=>
string(38) "JPMORGAN upgrades GSK to 'Underweight'"
["snippet_en"]=>
string(264) "January 5, 2024 - The US bank JPMorgan has left GSK's rating at 'Underweight' with a price target of 1,450 pence ahead of quarterly figures. The pharmaceutical company is likely to present a solid report overall, wrote analyst James Gordon in a report on Friday..."
["url"]=>
string(82) "https://www.wallstreet-online.de/nachricht/17679123-jpmorgan-stuft-gsk-underweight"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/6112e08c-4a54-4043-bc51-11ba58f7dafe"
["source"]=>
string(20) "wallstreet-online.de"
["publication_date"]=>
string(10) "2024-01-05"
["categories"]=>
array(3) {
[0]=>
string(24) "Quarterly/Annual Figures"
[1]=>
string(12) "Stock Market"
[2]=>
string(24) "Stock Research & Ratings"
}
}
[3]=>
array(7) {
["title_en"]=>
string(64) "GSK expects billions in sales with RSV vaccine in the first year"
["snippet_en"]=>
string(265) "The British pharmaceutical company GSK LSE:GSK expects sales of more than a billion pounds with its new RSV vaccine in the first year. “We are very pleased with the launch of our RSV vaccine,” said CEO Emma Walmsley in a Reuters Newsmaker interview on Thursday."
["url"]=>
string(68) "https://de.tradingview.com/news/reuters.com,2023:newsml_L8N3CV625:0/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/60984587-a55c-45a4-8e17-c6ec276b4ee9"
["source"]=>
string(15) "tradingview.com"
["publication_date"]=>
string(10) "2023-11-30"
["categories"]=>
array(2) {
[0]=>
string(24) "Quarterly/Annual Figures"
[1]=>
string(21) "Financial Performance"
}
}
[4]=>
array(7) {
["title_en"]=>
string(88) "Pharmaceutical manufacturer GSK is raising targets again - RSV vaccination is going well"
["snippet_en"]=>
string(277) "The pharmaceutical company GSK continued its good run with another surprisingly strong quarter. The management around company boss Emma Walmsley is now raising the bar for the year for a second time after the British suffered declining revenues in the third quarter of the year"
["url"]=>
string(97) "https://www.cash.ch/news/pharmahersteller-gsk-hebt-erneut-ziele-an-rsv-impfung-lauft-stark-652332"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/f519334f-2306-475d-b9a8-ed12981f0dd0"
["source"]=>
string(7) "cash.ch"
["publication_date"]=>
string(10) "2023-11-01"
["categories"]=>
array(2) {
[0]=>
string(24) "Quarterly/Annual Figures"
[1]=>
string(31) "Financial Update/Profit Warning"
}
}
[5]=>
array(7) {
["title_en"]=>
string(54) "Is Bunzl an overlooked dividend stock to consider now?"
["snippet_en"]=>
string(126) "FTSE 100 dividend stock Bunzl has been growing its shareholder payment at a compound annual growth rate of an attractive 8.5%."
["url"]=>
string(88) "https://www.fool.co.uk/2023/10/24/is-bunzl-an-overlooked-dividend-stock-to-consider-now/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/55ef8d21-529d-4b5c-920f-41c4e8ecb7d8"
["source"]=>
string(10) "fool.co.uk"
["publication_date"]=>
string(10) "2023-10-24"
["categories"]=>
array(3) {
[0]=>
string(24) "Quarterly/Annual Figures"
[1]=>
string(12) "Stock Market"
[2]=>
string(9) "Valuation"
}
}
[6]=>
array(7) {
["title_en"]=>
string(59) "GSK's New Drugs and Pipeline Hold the Key to Growth in 2023"
["snippet_en"]=>
string(176) "GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion."
["url"]=>
string(74) "https://finance.yahoo.com/news/gsks-drugs-pipeline-hold-key-122112914.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/de04b0f2-fa51-4468-a62d-a83f954da769"
["source"]=>
string(9) "yahoo.com"
["publication_date"]=>
string(10) "2023-01-03"
["categories"]=>
array(1) {
[0]=>
string(24) "Quarterly/Annual Figures"
}
}
[7]=>
array(7) {
["title_en"]=>
string(66) "PharmaSGP Holding: Integration of GSK's OTC brands worked smoothly"
["snippet_en"]=>
string(200) "According to preliminary figures, PharmaSGP Holding achieved an increase in sales from 26.4 million euros to 42 million euros in the first half of 2022. On an EBITDA basis, the profit was 11.6 million"
["url"]=>
string(151) "https://www.finanznachrichten.de/nachrichten-2022-09/56953549-pharmasgp-holding-integration-der-otc-marken-von-gsk-hat-reibungslos-funktioniert-424.htm"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/42515c48-f6c9-4201-98ce-b2e7503f5e5a"
["source"]=>
string(20) "finanznachrichten.de"
["publication_date"]=>
string(10) "2022-09-01"
["categories"]=>
array(3) {
[0]=>
string(18) "General Investment"
[1]=>
string(24) "Quarterly/Annual Figures"
[2]=>
string(19) "Investment Requests"
}
}
[8]=>
array(7) {
["title_en"]=>
string(50) "GSK consumer health spin-off Haleon starts trading"
["snippet_en"]=>
string(299) "GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion). The new company– which has achieved the largest London listing in a decade– has annual sales of"
["url"]=>
string(80) "https://pharmaphorum.com/news/gsk-consumer-health-spin-off-haleon-starts-trading"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/c103aeff-d491-48f8-9773-cc329e43e37c"
["source"]=>
string(16) "pharmaphorum.com"
["publication_date"]=>
string(10) "2022-07-18"
["categories"]=>
array(8) {
[0]=>
string(12) "Going Public"
[1]=>
string(15) "Market Movement"
[2]=>
string(8) "spin-off"
[3]=>
string(11) "Competition"
[4]=>
string(25) "Business Model Resilience"
[5]=>
string(9) "Valuation"
[6]=>
string(24) "Quarterly/Annual Figures"
[7]=>
string(20) "Conflict of Interest"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(30)
}
[1]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(27)
}
[2]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(26)
}
[3]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(23)
}
[4]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(20)
}
[5]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(18)
}
[6]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(17)
}
[7]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(17)
}
[8]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(17)
}
[9]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(14)
}
[10]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(14)
}
[11]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(13)
}
[12]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(12)
}
[13]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(11)
}
[14]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(10)
}
[15]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(10)
}
[16]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(9)
}
[17]=>
array(2) {
["name"]=>
string(20) "Business Development"
["count"]=>
int(9)
}
[18]=>
array(2) {
["name"]=>
string(6) "Crisis"
["count"]=>
int(9)
}
[19]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(8)
}
[20]=>
array(2) {
["name"]=>
string(13) "Data Security"
["count"]=>
int(8)
}
[21]=>
array(2) {
["name"]=>
string(16) "Customer Welfare"
["count"]=>
int(7)
}
[22]=>
array(2) {
["name"]=>
string(10) "Divestment"
["count"]=>
int(6)
}
[23]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(6)
}
[24]=>
array(2) {
["name"]=>
string(21) "Cultural developments"
["count"]=>
int(6)
}
[25]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(6)
}
[26]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(6)
}
[27]=>
array(2) {
["name"]=>
string(24) "Employee Health & Safety"
["count"]=>
int(6)
}
[28]=>
array(2) {
["name"]=>
string(19) "Economic Conditions"
["count"]=>
int(6)
}
[29]=>
array(2) {
["name"]=>
string(7) "Layoffs"
["count"]=>
int(6)
}
}
}
4abba-us-gsk-consumer-health-inc
Gsk Consumer Health, Inc.
Location
New Jersey
Founded
1994-02-28
Website
https://www.gsk.com
Articles
458 Articles
Category
Pharmaceutical Preparations
Description
GSK Consumer Healthcare is a global business that discovers, develops, and manufactures innovative consumer healthcare products. It is an associate of GlaxoSmithKline plc, one of the world's largest healthcare companies. GSK Consumer Healthcare aims to become one of the world's most innovative, best performing, and trusted healthcare companies. Their goal is to improve lives through scientific innovation, build category-defining brands, and become Pakistan's first and best Fast Moving Consumer Healthcare Company.
Global stock markets remained on an upbeat trajectory in March, with the European stock markets particularly robust in the first quarter. Banking and Energy stocks shone, outpacing the technology sector in March.
January 5, 2024 - The US bank JPMorgan has left GSK's rating at 'Underweight' with a price target of 1,450 pence ahead of quarterly figures. The pharmaceutical company is likely to present a solid report overall, wrote analyst James Gordon in a report on Friday...
The British pharmaceutical company GSK LSE:GSK expects sales of more than a billion pounds with its new RSV vaccine in the first year. “We are very pleased with the launch of our RSV vaccine,” said CEO Emma Walmsley in a Reuters Newsmaker interview on Thursday.
The pharmaceutical company GSK continued its good run with another surprisingly strong quarter. The management around company boss Emma Walmsley is now raising the bar for the year for a second time after the British suffered declining revenues in the third quarter of the year
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.
According to preliminary figures, PharmaSGP Holding achieved an increase in sales from 26.4 million euros to 42 million euros in the first half of 2022. On an EBITDA basis, the profit was 11.6 million
GSK's consumer health spinout Haleon started trading on the London Stock Exchange this morning, making its debut with a price of 330 pence and a market valuation of around £31 billion ($37 billion). The new company– which has achieved the largest London listing in a decade– has annual sales of
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
